JAK Inhibitors for Treatment of Alopecia Areata

    July 2018 in “ ˜The œjournal of investigative dermatology/Journal of investigative dermatology ”
    Eddy H.C. Wang, B. Sallee, Christina I. Tejeda, Angela M. Christiano
    Studysummary In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jidonline.org →
    Discuss this study in the Community →

    Research cited in this study 30

    1. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    2. Novel Therapies for Alopecia Areata: The Era of Rational Drug Development The Journal of Allergy and Clinical Immunology · 2017
    3. Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2017
    4. Alopecia Areata: Treatment Options and Efficacy Journal of the American Academy of Dermatology · 2017
    5. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    6. Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata Journal of the American Academy of Dermatology · 2017
    7. Treatment of Alopecia Areata With Tofacitinib JAMA Dermatology · 2017
    8. Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring International Journal of Dermatology · 2017
    9. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017
    10. Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
    11. Reversal of Alopecia Universalis by Tofacitinib: A Case Report Annals of Internal Medicine · 2016
    12. Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents Journal of the American Academy of Dermatology · 2016
    13. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    14. Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report Case Reports in Dermatology · 2016
    15. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    16. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    17. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman Acta dermato-venereologica · 2016
    18. Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients Journal of the European Academy of Dermatology and Venereology · 2016
    19. Familial Aggregation of Alopecia Areata Journal of the American Academy of Dermatology · 2016
    20. ULBP3: A Marker for Alopecia Areata Incognita Archives of Dermatological Research · 2016
    21. Transient Efficacy of Tofacitinib in Alopecia Areata Universalis Case Reports in Dermatology · 2016
    22. Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies Autoimmunity reviews · 2016
    23. Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata Journal of the American Academy of Dermatology · 2015
    24. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis JAMA Dermatology · 2015
    25. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    26. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014
    27. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    28. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014
    29. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010
    30. Type 1 Interferon Signature in the Scalp Lesions of Alopecia Areata British Journal of Dermatology · 2010

    Related research 3

    1. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    2. Linear Alopecia Areata JAAD case reports · 2018
    3. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018